miR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function

A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide

BACKGROUND Dulaglutide is a new, long-acting glucagon-like peptide analogue in the treatment of type 2 diabetes. It is available in two doses, 0.75 and 1.5 mg, given by injection once weekly. This systematic review reports the effectiveness and safety of dulaglutide in type 2 diabetes in dual and triple therapy. METHODS MEDLINE, MEDLINE In-Process and Other Non-Indexed Citations, EMBASE, and ...

Equine glucagon-like peptide-1 receptor physiology

Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased insulin response to carbohydrate intake in animals with EMS. However, little is known about the equine GLP-1 receptor (eGLP-1R), or whether GLP...

Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.

This review analyses a recent advance in diabetes pharmacotherapeutics: the combination of insulin and glucagon-like peptide 1 receptor agonists (GLP 1 RA). It describes the rationale for such a combination, and discusses the impact of such therapy on glycaemic control. The paper also assesses other benefits of the combination, and provides a practical framework for pragmatic, rational use of t...

S17 Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist

Combining a Glucagon-like Peptide-1 Receptor Agonist with Basal Insulin: The Why and How

Case Study Mary is a 61 year-old female diagnosed with type 2 diabetes mellitus (T2DM) 8 years ago. She was initially managed with the combination of lifestyle modification and metformin. Since that time she was treated with a sulfonylurea, but it was discontinued due to symptomatic hypoglycemia. She was also treated with pioglitazone, but significant fluid retention led to it discontinuation. ...